SCHEMBL17566751

SCHEMBL17566751

c1ccc(-c2cc3c(-c4nc5ccccc5[nH]4)n[nH]c3cn2)nc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
WNT1 P04628 9/20 0.70
TGFBR1 P36897 7/20 0.70
CLK2 P49760 2/20 0.70
CLK3 P49761 2/20 0.70
DYRK1A Q13627 2/20 0.70
PIM1 P11309 5/20 0.67
FGFR1 P11362 1/20 0.59
FLT1 P17948 1/20 0.59
NPC1 O15118 1/20 0.58
LMNA P02545 1/20 0.58
PKM P14618 1/20 0.58
HPGD P15428 1/20 0.58
MTOR P42345 1/20 0.58
METAP2 P50579 1/20 0.58
RAB9A P51151 1/20 0.58
METAP1 P53582 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
PDPK1 O15530 2/20 0.57
CHEK1 O14757 2/20 0.53
PIM2 Q9P1W9 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17568380 0.90 WNT1 (0.63) WNT1TGFBR1CLK2CLK3DYRK1A
SCHEMBL17566747 0.88 WNT1 (0.74) WNT1TGFBR1CLK2CLK3DYRK1A
SCHEMBL17591970 0.88 PIM1 (0.64) WNT1TGFBR1CLK2CLK3DYRK1A
SCHEMBL17566749 0.84 WNT1 (0.79) WNT1TGFBR1CLK2CLK3DYRK1A
SCHEMBL17566680 0.84 WNT1 (0.78) WNT1TGFBR1CLK2CLK3DYRK1A
SCHEMBL17566007 0.83 WNT1 (0.81) WNT1TGFBR1CLK2CLK3DYRK1A
SCHEMBL4036858 0.83 PDPK1 (0.64) WNT1TGFBR1CLK2CLK3DYRK1A
SCHEMBL17568322 0.82 PIM1 (0.67) WNT1TGFBR1CLK2CLK3DYRK1A
SCHEMBL17556384 0.82 CLK2 (1.00) WNT1TGFBR1CLK2CLK3DYRK1A
SCHEMBL17566735 0.81 WNT1 (0.71) WNT1TGFBR1CLK2CLK3DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190119276-A1 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF SAMUMED, LLC 2019-04-25 US claimed
US-10202377-B2 3-(1H-benzo[D]imidazol-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2019-02-12 US claimed
US-20180086754-A1 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2018-03-29 US claimed
US-9657016-B2 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2017-05-23 US claimed
WO-2016040180-A1 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF SAMUMED, LLC (US) 2016-03-17 WO claimed
US-20190119276-A1 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF SAMUMED, LLC 2019-04-25 US disclosed
US-10202377-B2 3-(1H-benzo[D]imidazol-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2019-02-12 US disclosed
US-20180086754-A1 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2018-03-29 US disclosed
US-20180086754-A1 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2018-03-29 US disclosed
US-9657016-B2 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2017-05-23 US disclosed
US-9657016-B2 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2017-05-23 US disclosed
US-20160068529-A1 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2016-03-10 US disclosed
US-20160068529-A1 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2016-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160068529-A1 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF WNT1, WNT3, WNT3A WNT1 1/4885TGFBR1 625/4885CLK2 1984/4885
US-20180086754-A1 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF WNT1, WNT3, WNT3A WNT1 1/4885TGFBR1 625/4885CLK2 1984/4885
US-10202377-B2 3-(1H-benzo[D]imidazol-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof WNT1, WNT3, WNT3A WNT1 1/4885TGFBR1 625/4885CLK2 1984/4885
US-20190119276-A1 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF WNT1, WNT3, WNT3A WNT1 1/4885TGFBR1 625/4885CLK2 1984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.